Enlivex Completes Patient Enrollment for Phase II COVID-19 Trial
Ticker: ENLV · Form: 6-K · Filed: Apr 21, 2025 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial, biotech, covid-19
TL;DR
Enlivex just finished enrolling patients for its Phase II COVID-19 drug trial. Big step for their Allocetra therapy.
AI Summary
On April 21, 2025, Enlivex Therapeutics Ltd. announced the completion of patient enrollment for the Phase II stage of its randomized, controlled, blinded Phase I/II clinical trial. This trial is investigating the safety and efficacy of Allocetra, Enlivex's universal cell therapy candidate, for treating patients with severe COVID-19. The company, formerly known as Bioblast Pharma Ltd., is based in Tel Aviv, Israel.
Why It Matters
The completion of patient enrollment is a significant step towards potentially validating Allocetra as a treatment for severe COVID-19, which could impact future treatment protocols and patient outcomes.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with outcomes dependent on efficacy and safety data, and regulatory approvals.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Allocetra (drug) — Investigational therapy
- Bioblast Pharma Ltd. (company) — Former company name
- April 21, 2025 (date) — Announcement date
FAQ
What is the primary purpose of the Phase I/II clinical trial mentioned in the filing?
The trial is investigating the safety and efficacy of Allocetra for treating patients with severe COVID-19.
What is the name of Enlivex Therapeutics' cell therapy candidate?
The cell therapy candidate is named Allocetra.
When did Enlivex Therapeutics announce the completion of patient enrollment?
Enlivex Therapeutics announced the completion of patient enrollment on April 21, 2025.
What was Enlivex Therapeutics Ltd. formerly known as?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd.
In which country is Enlivex Therapeutics Ltd. organized?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 21, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).